Company Overview
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology firm dedicated to developing targeted bacteriophage therapeutics designed to treat antibiotic-resistant infections globally. The company leverages its proprietary bacteriophage-based technology to create products that address critical challenges in the healthcare sector. This entity functions within the broader Healthcare sector and the specific Biotechnology industry, where it focuses on innovation rather than established revenue streams from mature products. As of the latest reporting period, the company holds a market capitalization of $313.46M, generated annual revenue of $5.05M, and employs a workforce of 60 individuals. The market capitalization figure of $313.46M combined with the relatively modest annual revenue of $5.05M indicates that the company is in an early-stage development phase where valuation is driven by potential future clinical outcomes rather than current profitability. The small employee base of 60 suggests a lean operational structure typical of clinical-stage entities that are scaling their research and development efforts without the overhead of a large commercial sales force.
Financial Health
The company reported revenue of $5.05M over the trailing twelve months, accompanied by a net income loss of $-46,901,000 and an EBITDA of $-31,857,000. The substantial gap between the $5.05M revenue and the $-46,901,000 net income reveals a cost structure characterized by heavy expenditures on research, development, and clinical trial activities that far exceed current sales generation. Free cash flow stands at $-25,217,250, which signifies that the company is consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity for shareholders or debt repayment. The gross margin is reported at 0.0%, while the operating margin is significantly negative at -670.9%, and the profit margin is also 0.0%; these figures collectively indicate that the company has not yet achieved commercial scalability or cost efficiencies typical of mature pharmaceutical firms. In terms of liquidity and solvency, the company holds $14.76M in cash against $177.68M in debt, resulting in a debt-to-equity ratio that is effectively N/A due to the negative equity position. The current ratio is 0.12, which indicates a severe short-term liquidity constraint where current liabilities exceed current assets, suggesting the company relies on external financing to meet its obligations. Return on Equity is listed as N/A because of the negative equity base, while the return on assets is -22.2%, which reveals that management is currently utilizing the company's asset base to generate negative returns rather than positive value creation.
Valuation Assessment
Valuation metrics for Armata Pharmaceuticals reflect the high-risk nature of its clinical-stage business model. The trailing P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E is -5.48, a figure that implies the market is pricing in continued negative earnings or a lack of expected profitability in the near term. The price-to-book ratio stands at -3.26, indicating that the market values the company at a significant discount relative to its book value, which is common for companies with substantial intangible assets or negative net asset positions. Alternative valuation multiples such as the price-to-sales ratio of 62.02 and the EV/EBITDA of -14.93 suggest that investors are pricing the company based on its potential asset value and pipeline rather than current cash flows or earnings power. The stock has exhibited significant price volatility over the past year, trading between a 52-week high of $16.34 and a 52-week low of $0.90. Given the wide range between the high and low, the current trading price sits at a level that reflects high uncertainty, though the specific percentage distance from the high or low requires the current price input which is not provided in the facts; however, the range itself demonstrates a beta of 1.39. This beta value of 1.39 indicates that the stock is expected to be more volatile than the broader market, moving with greater amplitude than the general market index.
Growth & Income
The company's financial trajectory shows a revenue growth rate of -61.0% year over year, while the earnings growth rate is N/A due to negative earnings. The decline in revenue indicates a contraction in sales or a lag in commercialization relative to the company's development pipeline, suggesting that revenue is currently growing slower than the potential of the pipeline would allow. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute any cash to shareholders. Consequently, the company reinvests its limited financial resources and any potential future earnings back into its research and development efforts to advance its bacteriophage therapeutics rather than paying dividends. The overall growth and income profile is characterized by negative revenue momentum and a lack of current income generation, typical of a clinical-stage biotechnology company that prioritizes capital expenditure for product development over immediate shareholder returns or profitability.